Sulfacytine

Summary

Sulfacytine (CHEMBL1201056) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 294.33 Da · C12H14N4O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201056
Name	Sulfacytine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5322
Molecular formula	C12H14N4O3S
Molecular weight	294.33
InChIKey	SIBQAECNSSQUOD-UHFFFAOYSA-N

SMILES: CCN1C=CC(=NC1=O)NS(=O)(=O)C2=CC=C(C=C2)N

IUPAC name: 4-amino-N-(1-ethyl-2-oxopyrimidin-4-yl)benzenesulfonamide

Also known as: CI-636, NSC-356717, Renoquid, Sulfacitina, Sulfacitine, Sulfacytine, SULFACYTINE, SID170465286

Patent coverage: 988 distinct patent families (3,866 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).